ERBB2 (V777L)
Sign in to save this workspaceERBB2 · Variant type: point · HGVS: p.V777L
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Canertinib | 99.9% | 0.1% | 96.49 |
| 2 | Mobocertinib | 99.8% | 0.2% | 97.22 |
| 3 | Osimertinib | 99.8% | 0.2% | 97.24 |
| 4 | Pralsetinib | 98.8% | 1.2% | 93.43 |
| 5 | Dacomitinib | 98.8% | 1.2% | 97.99 |
| 6 | Lazertinib | 98.8% | 1.2% | 97.47 |
| 7 | Brigatinib | 98.1% | 1.9% | 82.96 |
| 8 | Afatinib | 98.1% | 1.9% | 98.50 |
| 9 | Darovasertib | 96.9% | 3.1% | 96.99 |
| 10 | Neratinib | 96.8% | 3.2% | 93.18 |
| 11 | Erlotinib | 91.8% | 8.2% | 99.75 |
| 12 | Bosutinib | 91.7% | 8.3% | 87.22 |
| 13 | Gefitinib | 91.6% | 8.4% | 99.25 |
| 14 | Ibrutinib | 90.8% | 9.2% | 94.74 |
| 15 | Vandetanib | 90.3% | 9.8% | 95.74 |
| 16 | Lapatinib | 88.7% | 11.3% | 99.25 |
| 17 | Fostamatinib | 88.2% | 11.8% | 96.74 |
| 18 | Ponatinib | 86.8% | 13.2% | 78.23 |
| 19 | Avapritinib | 70.3% | 29.8% | 97.73 |
| 20 | Alectinib | 65.8% | 34.2% | 95.49 |
| 21 | Dasatinib | 57.2% | 42.8% | 87.97 |
| 22 | Pacritinib | 57.2% | 42.8% | 88.64 |
| 23 | Alpelisib | 53.6% | 46.4% | 97.22 |
| 24 | Nintedanib | 50.9% | 49.1% | 90.23 |
| 25 | Mitapivat | 38.8% | 61.2% | 100.00 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Canertinib | 99.9% | — | — |
| Mobocertinib | 99.8% | — | — |
| Osimertinib | 99.8% | — | — |
| Pralsetinib | 98.8% | — | — |
| Dacomitinib | 98.8% | — | — |
| Lazertinib | 98.8% | — | — |
| Brigatinib | 98.1% | — | — |
| Afatinib | 98.1% | — | — |
| Darovasertib | 96.9% | — | — |
| Neratinib | 96.8% | — | — |
| Erlotinib | 91.8% | — | — |
| Bosutinib | 91.7% | — | — |
| Gefitinib | 91.6% | — | — |
| Ibrutinib | 90.8% | — | — |
| Vandetanib | 90.3% | — | — |
| Lapatinib | 88.7% | — | — |
| Fostamatinib | 88.2% | — | — |
| Ponatinib | 86.8% | — | — |
| Avapritinib | 70.3% | — | — |
| Alectinib | 65.8% | — | — |
| Dasatinib | 57.2% | — | — |
| Pacritinib | 57.2% | — | — |
| Alpelisib | 53.6% | — | — |
| Nintedanib | 50.9% | — | — |
| Mitapivat | 38.8% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_breast | Breast | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.4ms